Stock Price Movements and Positive Quarterly Results - Research Report on Waters, PerkinElmer, DENTSPLY, NxStage, and ICON

News provided by

Nov 14, 2013, 08:00 ET

NEW YORK, November 14, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Waters Corporation (NYSE: WAT),

PerkinElmer, Inc. (NYSE: PKI), DENTSPLY International Inc. (NASDAQ: XRAY), NxStage Medical, Inc. (NASDAQ: NXTM), and ICON plc. (NASDAQ: ICLR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Waters Corporation Research Report

On November 7, 2013, Waters Corporation (Waters) ended the day with stocks closing at $98.45, down 1.24%. Over the past three trading sessions, Waters' stocks fell 2.33% while the Dow Jones Industrial Average slid 0.29% during the same period. The Full Research Report on Waters Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2fff_WAT]

PerkinElmer, Inc. Research Report

On October 30, 2013, PerkinElmer, Inc. (PerkinElmer) announced its Q3 FY 2013 financial results (period ended September 29, 2013) with revenues up 2.9% YoY to $524.3 million. The Company's operating income from continuing operations increased 32.3% YoY to $57.2 million during the quarter. Net Income from continuing operations totaled $40.3 million or $0.36 per diluted share in Q3 FY 2013 versus $29 million or $0.25 per diluted share in Q3 FY 2012. Robert Friel, Chairman and CEO of PerkinElmer said, "I am pleased with our third quarter performance as we were able to grow both revenue and adjusted earnings per share and expand operating margins. While I remain encouraged by the resiliency we are seeing across much of the portfolio, the global economic environment remains challenging. We believe, however, that the growth and productivity investments deployed over the past year should help us in the successful delivery of our full year commitments as we build a strong foundation for the future." For full-year 2013, PerkinElmer expects EPS from continuing operations to be in the range of $1.42 to $1.45 and non-GAAP EPS to be within $2.04 to $2.07. The Full Research Report on PerkinElmer, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2016_PKI]

DENTSPLY International Inc. Research Report

On November 7, 2013, stocks of DENTSPLY International Inc. (DENTSPLY) fell 0.38% to $47.15 at the end of trading. DENTSPLY's stocks slid 0.63% over the previous three trading sessions, while the Dow Jones Industrial Average fell 0.29% during the same period. The Full Research Report on DENTSPLY International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/6b01_XRAY]

NxStage Medical, Inc. Research Report

On November 7, 2013, NxStage Medical, Inc (NxStage) reported its Q3 2013 financial results with revenues up 9.4% YoY to $66.9 million. NxStage stated that the increase in revenue was driven by increased adoption of the NxStage® System One™. For Q3 2013 the Company also reported a 5.6% YoY increase in home revenues to $33.7 million. Jeffrey H. Burbank, Founder and CEO of NxStage said, "We continue to make solid progress in strategic areas that are focused on accelerating growth over the longer term. We're seeing good momentum in the domestic market and believe our growth opportunity here remains very robust. In addition to our direct to patient marketing initiatives, we have a significant opportunity to improve our patients' experiences and increase adoption of our therapies with both our innovative product pipeline and our centers of excellence." For Q4 2013, NxStage expects revenues to be within $67.0 and $68.5 million, and net loss in the range of $6.0 million to $5.0 million. The Company also announced that the US Food and Drug Administration (FDA) has cleared the Company's Nx2me Connected Health™ solution that provides new features and capabilities that are important to home dialysis patients and nurse, and expects to begin offering Nx2me in the US later in 2013. The Full Research Report on NxStage Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4654_NXTM

ICON plc Research Report

On November 7, 2013, ICON plc's (ICON) ordinary shares rose 1.09% to end the day at $40.83. Over the past three trading sessions, ICON's stock rose to 0.07% while the Dow Jones Industrial Average slid 0.29% during that period. The Full Research Report on ICON plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/fbb0_ICLR]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner